Date: 2012-02-28
Type of information: Private placement
Company: BiolineRx (Israel)
Investors: healthcare-focused U.S. institutional investors
Amount: $15 million (€ 11.2 million)
Funding type: private placement
Planned used: The Company expects to use the net proceeds from the offering for working capital and for continued development of the Company’s 18 compounds.
Others: * On February 28, 2012, BioLineRx has announced that it has closed its previously announced $15 million private placement to healthcare-focused U.S. institutional investors. As a result, the Company sold approximately 5.25 million American Depositary Shares (\"ADSs”) at a purchase price of $2.86 per ADS, and warrants to purchase up to 2.6 million additional ADSs at an exercise price of $3.57 per ADS. After fees and estimated offering expenses, the Company received net proceeds of approximately $14.1 million. Roth Capital Management, LLC acted as the sole placement agent to BioLineRx Ltd. for the offering.
Therapeutic area:
